---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009885"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:56:10.991217+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics raises $50M in equity financing at 30% premium; extends cash into H1 2028

## Summary
- Gross proceeds ~$50M from sale of 2M shares ($6.71) and pre-funded warrants; includes Series 1 warrants ($13.42) and Series 2 warrants ($20.13).
- Offering priced at 30% premium to Jan 9, 2026 closing; investors include BVF Partners, Deerfield Management, Flagship Pioneering, and a biotech mutual fund.
- Pro forma cash, cash equivalents and marketable securities of $208.9M (unaudited) as of Jan 13, 2026; cash runway extended into first half of 2028.
- FHD-909 (SMARCA2 inhibitor) Phase 1 dose-escalation trial on track; enrollment in NSCLC patients progressing as planned.
- Selective CBP degrader on track to be IND-ready in 2026; selective EP300 degrader expected to enter IND-enabling studies in 2026; ARID1B degrader advancing to in vivo PoC in 2026.

## SEC filing metadata
- accession: 0001193125-26-009885
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/0001193125-26-009885-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000119312526009885/d31462d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009885
- JSON: https://secwatch.observer/filing/0001193125-26-009885.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009885.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.